News

The importance of patient stratification methods based on AI for disease onset and progression prediction

The importance of patient stratification methods based on AI for disease onset and progression prediction
AI

The inherent complexity of degenerative neurological diseases, such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), and the particular requirement for unravelling new biomarkers warrant a novel approach that integrates biological, clinical, environmental and all other potentially relevant data sources. This heterogeneous data would also be crucial to developing advanced descriptive and predictive models that help medical doctors and enable a more personalized approach. Artificial intelligence (AI), specifically, plays a fundamental role in this step through the time-sensitive analysis of such data sources, including those of genotype-phenotype, clinical temporal, and remote patient monitoring.

The importance of AI-based methods is indeed relevant in discovering significant patterns that are usually too complex to be observed manually or through simple automated approaches. Hence, developing AI-based patient stratification methods is integral to deepening our understanding of patient profiles; improving prognosis of disease progression and its evolution patterns; and providing early-risk prediction tools. In turn, we can achieve personalized treatments through targeted therapies, optimize medical interventions to focus on disease-specific progression rates or avoid unnecessary hospitalizations, and estimate the impact of therapy, i.e., the probability of adverse effects or other complications. In addition, AI-based models could support patient healthcare, providing important predictions about therapies and risk factors.

In this respect, by integrating multiple and heterogeneous data, from clinical to environmental, BRAINTEASER aims to develop AI-based models for patient stratification and disease progression for two challenging degenerative neurological diseases, ALS and MS. It will also aim to develop tools for early-risk prediction of disease progression and adverse events. Through identifying patient profiles and integrating different models and tools, BRAINTEASER will contribute to developing personalized approaches that can lead to better patient prognosis and supportive care.

NEWS​

Related News

Scaling Up Digital Health Innovations: An Interview with Anne Moen

23 May 2024
An exclusive interview on overcoming challenges and seizing opportunities in healthcare technology deployment at HLTH Europe

The Convening Power of ECHAlliance: Spanish Ecosystem Gathering

21 May 2024
How ECHAlliance's convening power brought together Spanish health innovators for unprecedented networking and knowledge sharing

Creating the action plan for the Baltic-Nordic biotech cluster

21 May 2024
Fill in the survey for the BIOCONNECT EU Project and help our Lithuanian Ecosystem to develop an integrated innovation action plan for a more intercon...

A Shift to Value-Based Procurement in Digital Health Solutions

16 May 2024
The shift towards value-based procurement in healthcare, focusing on long-term effectiveness and patient outcomes, rather than initial costs. The Dire...

Launching Moxiam+: the digital companion for an active and independent senior lifestyle

16 May 2024
Embark on a journey with Sweden-based Moxiam, the vanguard of digital health innovation dedicated to enriching the lives of seniors. Moxiam leverages ...

Romania – Transylvania Digital Health Ecosystem by FreshBlood is ECHAlliance Ecosystem of the Month – May

15 May 2024
This month we are featuring our Transylvania Digital Health Ecosystem by FreshBlood from Romania as our Ecosystem of the Month.

Become a member

Join ECHAlliance to amplify your organisation’s message, grow your networks, connect with innovators and collaborate globally.
 
First name *
Last Name *
Email Address *
Country *
Position *
First name *
Last Name *
Email Address *
Country *
Position *